Business Description
T2 Biosystems Inc
NAICS : 325413
SIC : 2835
ISIN : US89853L1044
Description
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | -0.81 | |||||
| Debt-to-Equity | -1.77 | |||||
| Debt-to-EBITDA | -1.13 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -28.38 | |||||
| Beneish M-Score | -3.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -84.6 | |||||
| 3-Year EBITDA Growth Rate | 78 | |||||
| 3-Year EPS without NRI Growth Rate | 78.2 | |||||
| 3-Year FCF Growth Rate | 78.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.5 | |||||
| 9-Day RSI | 11.78 | |||||
| 14-Day RSI | 22.85 | |||||
| 6-1 Month Momentum % | 8.54 | |||||
| 12-1 Month Momentum % | -84.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.45 | |||||
| Quick Ratio | 0.36 | |||||
| Cash Ratio | 0.28 | |||||
| Days Inventory | 107.66 | |||||
| Days Sales Outstanding | 75.04 | |||||
| Days Payable | 44.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.9 | |||||
| Shareholder Yield % | -202.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -113.58 | |||||
| Operating Margin % | -655.54 | |||||
| Net Margin % | -696.19 | |||||
| FCF Margin % | -672.56 | |||||
| ROA % | -137.37 | |||||
| ROIC % | -109.13 | |||||
| ROC (Joel Greenblatt) % | -383.98 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.15 | |||||
| EV-to-EBIT | -1.29 | |||||
| EV-to-Forward-EBIT | -1.71 | |||||
| EV-to-EBITDA | -1.31 | |||||
| EV-to-Revenue | 8.01 | |||||
| EV-to-Forward-Revenue | 3.42 | |||||
| EV-to-FCF | -1.19 | |||||
| Earnings Yield (Greenblatt) % | -77.52 | |||||
| FCF Yield % | -202.81 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers